drugset / Trial / NCT00819351

ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase

NCT00819351

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate if intramuscular PEG-asparaginase administered either at six or two week intervals from day 92 until 8 months from diagnosis for patients with non-HR ALL will result in equal probability of Event Free Survival

Timeline

Start
2009-01-01
Primary completion
2016-03-02
Completion
2016-03-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegaspargase Protein / enzyme biologic 1000 iu Intramuscular